DDInter927 DDInter648
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Disopyramide
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Entrectinib may lead to a major life threatening interaction when taken with Disopyramide
Entrectinib may lead to a major life threatening interaction when taken with Macimorelin